Definium Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Definium Therapeutics Inc DFTX.OQ reported a quarterly adjusted loss of 50 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -41 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -74 cents to -46 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Definium Therapeutics Inc's reported EPS for the quarter was a loss of 78 cents​.

• The company reported a quarterly loss of $67.27 million.

• Definium Therapeutics Inc shares had risen by 31.6% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.6% in the last three months.​

• In the last 30 days, seven analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Definium Therapeutics Inc is $26.50, about 33.5% above its last closing price of $17.62

This summary was machine generated from LSEG data February 26 at 10:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)